医疗机构中药制剂创新和持续发展能力评价研究

目的 对医疗机构中药制剂创新和持续发展能力进行综合评价,为行政管理部门决策及各医院中药制剂可持续发展提供参考。方法 以浙江省133家医疗机构中药制剂调研数据为对象,利用层次分析法构建医疗机构中药制剂创新和持续发展能力评价体系,通过反向传播神经网络构建中药制剂室/中心评价体系预测模型。结果 构建的医疗机构中药制剂创新和持续发展能力评价指标体系包含4项二级指标以及19项三级指标,其中研发品种数、超百万品种数、注册品种数、研发方式、制剂室面积指标的权重值较高,分别为 0.15758、0.12928、0.09343、0.07879和0.07458。熵权法结合层次分析法的指标权重构建反向传播神经网络,Levenberg-Marquardt算法和Scaled Conjugate Gradient算法训练模型总体相关系数分别为0.98983和0.9348。结论 本研究构建了一个科学有效的医疗机构中药制剂创新和持续发展能力综合评价体系,可实现对医疗机构中药制剂综合能力的预测评价。     

重庆地区梅毒螺旋体基因分型及其临床相关性研究

目的：调查重庆地区梅毒螺旋体基因亚型的分布,初步探讨基因亚型与临床相关性。方法：收集2010年6月至2013年10月重庆地区421例梅毒标本,用巢式PCR检测梅毒螺旋体DNA多聚酶I基因（DNA polymerase I gene,polA）,然后扩增阳性标本酸性重复蛋白基因（acid repeat protein,arp）和苍白密螺旋体重复家族基因（treponema pallidum repeat,tpr）及TP0548基因,分别根据Pillay标准基因分型和三基因分型法进行分型,利用双侧Fisher’s exact test进行数据统计分析,初步探讨不同基因亚型与血清固定、梅毒复发和吉海反应的相关性。结果：163例标本polA PCR检测阳性,arp、tpr基因和TP0548基因亚型分别以14型、d型和f型为主。正规驱梅治疗12月后,32例患者血清固定,其中tpr基因d型（1１例）、a和b型（各2例）和f型（1例）;3例患者梅毒复发,其中TP0548基因c型（2例）和f型（1例）;8例发生吉海反应,其中14f/f（4例）,14d/f（3例）和未分型（1例）。结论：重庆地区梅毒螺旋体以14、d和f型为优势型。梅毒血清固定可能与tpr基因b型相关,14f/f基因型的二期梅毒患者易发生苄星青霉素治疗后的吉海反应。     

男男性行为者艾滋病暴露前预防用药性行为去抑制化情况

目的：了解男男性行为者（men who have sex with men,MSM）在参加暴露前预防用药（pre-exposure prophylaxis,PrEP）临床试验中是否存在性行为去抑制化现象及其影响因素。方法：采用非概率抽样法招募并筛选出108名MSM,随机分为77名服用药物组和31名空白对照组,第12、24、36、48周进行临床随访和问卷调查,问卷调查主要包括社会人口学特征,艾滋病相关知识、态度和行为等相关情况。采用单因素和多因素的广义估计方程分析MSM在参与PrEP中是否存在性行为去抑制化现象及其影响因素。结果：药物服用组MSM在参与PrEP的第12、24、36、48周的性伴个数中位数分别为1（0,6）、1（0,6）、1（0,10）、1（0,3）、1（0,3）,高危性行为次数中位数分别为1（0,26）、1.5（0,8）、1（0,12）、1（0,9）、2（0,30）;空白对照组性伴个数中位数分别为1（0,21）、1（0,2）、1（0,3）、1（0,3）、1（0,3）,高危性行为次数中位数分别为1（0,9）、1（0,6）、0.5（0,15）、0（0,10）、1（0,10）;多因素广义估计方程分析发现MSM在参与PrEP过程中性伴个数及高危性行为次数均没有发生改变（Z=-0.24,P=0.811;Z=0.93,P=0.355）,性行为方式为“1”和“0.5”的较性行为方式为“0”的拥有更多的性伴（Z=2.47,P=0.014;Z=2.24,P=0.025）;发生过商业性行为的MSM较没有发生过的拥有较少的性伴和高危性行为（Z=-2.82,P=0.005;Z=-2.28,P=0.023）;已婚较离异MSM发生较少的高危性行为次数（Z=-2.34,P=0.019）。结论：本研究中暂未发现PrEP中存在性行为去抑制化现象,性行为方式为“1”和“0.5”的MSM拥有较多性伴,是后期随访中的重点管理人群。还需进一步加强对艾滋病相关知识的科普。     

虎杖提取工艺初探

对乙肝康君虎杖进行单方水提、复方水提及７０％醇提工艺比较，结果７０％醇提，总蒽酯提取率为９６．７％，大黄素提取率为９６．１％，但经回收酒精，浓缩，干燥后，总蒽酯保留率为６８．９％，大黄素保留率为６５．６％。     

木耳菌丝体及其醇提物的药理作用

木耳菌丝体小鼠ip给药能明显提高外周血T淋巴细胞百分率,使环磷酰胺引起的半数溶血值HC₅₀减少恢复正常;其醇提物体内外均能明显抑制ADP诱导大鼠血小板聚集作用,缩短小鼠红细胞电泳时间。     

Didymin attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress

Objective: This study was designed to investigate the protective effects of didymin (Did) on doxorubicin (DOX)-induced cardiotoxicity. Methods: After pretreatment with Did (2, 4, 8 mg/kg intraperitoneal i.p.) for 7 d, the male C57 mice were injected with single dose of DOX (20 mg/kg i.p.). The cardioprotective effect of Did was observed on the 7th day after DOX treatment. Results: DOX delayed body growth and caused cardiac tissue injury, oxidative stress, and mitochondrial dysfunction. Similar experiments in H9C2 cardiomyocytes showed that DOX reduced cell viability, increased generation of reactive oxygen species (ROS) and fragmentation of DNA, decreased mitochondrial membrane potential, and induced cardiomyocyte apoptosis. However, all of these adverse effects were suppressed by Did pretreatment. Did increased protein expression of glutamate-L-cysteine ligase catalytic subunit (GCL), heme oxygenase 1 (HO-1), and nuclear factor erythroid 2-related factor 2 (Nrf2). Besides, Did also induced activation of PI3K/AKT. Conclusion: These findings indicated Did prevented DOX-induced cardiac injury and apoptosis via activating PI3K/AKT/Nrf2 signaling pathway.     

中药标准化提取物应用建议及产业化思考

"现代中药"是我国实施中药现代化而催生的具体产业方向。中药标准化提取物是现代中药的一种产品形式,中药提取过程是中药现代化的重要技术环节,提取物在国际市场上的应用是中药国际化的先行者和铺路石。中药提取物应是中药的一种产品方式。建议国家主管部门的产业发展规划与工作部署中应提高对涉及中药生产过程控制（中药材种植、提取工艺、装备及辅料应用）产业化项目的关注度,积极促进以中药标准化提取物投料的现代中药和保健品的开发研究和生产销售。     

大鼠视神经钳伤后外侧膝状体细胞损伤的研究

目的　探讨大鼠视神经钳伤后 ,外侧膝状体 (lateralgeniculatebody,LGB)细胞的损伤情况。方法　用 4 0g视神经损伤钳 ,压迫Sprague Dawley(SD)大鼠双侧视神经 30s,制成视神经部分定量损伤的动物模型。对LGB连续梯度切片 ,7d后用末端脱氧核苷酸转移酶介导的dUTP缺口末端标记法 (teriminaldeoxynucleotidyltransferase mediateddUTPnickend labeling ,TUNEL)对LGB细胞进行凋亡检测。 1个月后通过免疫组化染色技术 ,用兔抗鼠神经丝 (neurofilament,NF)单克隆抗体对LGB的神经元进行检测。同时经视觉中枢注入荧光染料颗粒蓝 ,对LGB细胞进行逆行荧光标记 ,在 70 0nm波长荧光显微镜下对连续切片的LGB标记细胞进行平均密度计数 ,并与对照组比较。结果　TUNEL法染色证实LGB细胞发生凋亡。对照组神经丝免疫组化染色呈清晰的条索状 ,而实验组明显减少。对照组LGB细胞密度均值为 (5 172± 2 4 8)个 /mm2 ,而损伤组LGB细胞密度均值为 (414 4± 6 1)个 /mm2 ,两组比较差异有非常显著意义 (t=8 995 ,P <0 0 1)。结论　在大鼠视神经钳伤后 ,LGB细胞受损 ,其损伤机制与凋亡有关     

Association of admission blood glucose level and clinical outcomes in elderly community‐acquired pneumonia patients with or without diabetes

IntroductionCommunity‐acquired pneumonia (CAP) is the major cause of infection‐related mortality worldwide. Patients with CAP frequently present with admission hyperglycemia.ObjectivesThe aim of this study was to evaluate the association between admission blood glucose (ABG) level and clinical outcomes in elderly CAP patients (≥80 years of age) with or without diabetes.MethodsIn this single center retrospective study, 290 elderly patients diagnosed with CAP were included. Demographic and clinical information were collected and compared. The associations between admission blood glucose level and the 30‐day mortality as well as intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) in elderly CAP patients with or without diabetes were assessed.ResultsOf the 290 eligible patients with CAP, 159 (66.5%) patients were male, and 64 (22.1%) had a known history of diabetes at hospital admission. After adjusting for age and sex, the logistic regression analysis had identified several risk factors that might be associated with clinical outcomes in elderly patients with CAP. Multivariable logistic regression analysis revealed that admission glucose level > 11.1 mmol/L was significant associated with ICU admission, IMV, and 30‐day mortality both in non‐diabetic and diabetic patients. Furthermore, Kaplan–Meier analysis indicated that patients with higher admission glucose level were correlated statistically significantly with 30‐day mortality in patients with CAP (P < 0.001).ConclusionAdmission blood glucose is correlated with 30‐day hospital mortality, ICU admission, and IMV of CAP in elderly patients with and without diabetes. Specially, admission glucose > 11.1 mmol/L was a significant risk factor for 30‐day hospital mortality.